Get the Stockscreener App
8.25
1.23%
0.10
Kura Oncology Inc stock is traded at $8.25, with a volume of 965.54K.
It is up +1.23% in the last 24 hours and up +11.64% over the past month.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.
See More
Previous Close:
$8.15
Open:
$8.28
24h Volume:
965.54K
Relative Volume:
0.49
Market Cap:
$628.49M
Revenue:
-
Net Income/Loss:
$-168.09M
P/E Ratio:
-3.8018
EPS:
-2.17
Net Cash Flow:
$-138.01M
1W Performance:
-0.36%
1M Performance:
+11.64%
6M Performance:
-58.69%
1Y Performance:
-58.73%
1-Day Range:
$8.1901
$8.355
1-Week Range:
$7.87
$8.55
52-Week Range:
$6.98
$24.17
Kura Oncology Inc Stock (KURA) Company Profile
Name
Kura Oncology Inc
Sector
Industry
Phone
(858) 500-8800
Address
12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA
Compare KURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
8.25 | 628.49M | 0 | -168.09M | -138.01M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-06-25 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-14-24 | Downgrade | Stifel | Buy → Hold |
| Dec-22-23 | Initiated | Mizuho | Buy |
| Aug-11-23 | Initiated | BofA Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| May-17-23 | Initiated | BTIG Research | Buy |
| Jan-31-23 | Initiated | Stifel | Buy |
| Jul-12-22 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-15-22 | Initiated | Jefferies | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-07-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| Nov-05-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Initiated | Credit Suisse | Outperform |
| May-05-20 | Initiated | Barclays | Overweight |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| Nov-09-18 | Initiated | Piper Jaffray | Overweight |
| Aug-01-18 | Initiated | H.C. Wainwright | Buy |
| Oct-13-16 | Resumed | Leerink Partners | Outperform |
| Jan-22-16 | Initiated | JMP Securities | Mkt Outperform |
| Dec-30-15 | Initiated | Oppenheimer | Outperform |
| Dec-16-15 | Initiated | Citigroup | Buy |
View All
Kura Oncology Inc Stock (KURA) Latest News
Analysts Set Kura Oncology, Inc. (NASDAQ:KURA) PT at $27.13 - MarketBeat
Kura Oncology to Report Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Will Kura Oncology's Q4 Earnings Reveal New Cancer Drug Progress? - StockTitan
Kura Oncology (KURA) to Release Earnings on Tuesday - MarketBeat
Kura Oncology, Inc. (NASDAQ:KURA) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Weekly Investment Analysts’ Ratings Updates for Kura Oncology (KURA) - Defense World
Kura Oncology's SWOT analysis: stock poised for pivotal year ahead - MSN
Barclays PLC Acquires 84,563 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - MarketBeat
FY2029 Earnings Forecast for Kura Oncology Issued By Wedbush - MarketBeat
Leerink Partnrs Estimates Kura Oncology Q1 Earnings - MarketBeat
Jennison Associates LLC Purchases New Holdings in Kura Oncology, Inc. (NASDAQ:KURA) - MarketBeat
BTIG Research Downgrades Kura Oncology (NASDAQ:KURA) to Neutral - MarketBeat
Kura Oncology (NASDAQ:KURA) Stock Price Expected to Rise, Wedbush Analyst Says - MarketBeat
Kura Oncology (NASDAQ:KURA) Shares Gap DownHere's What Happened - MarketBeat
Kura Oncology's (KURA) Market Outperform Rating Reaffirmed at JMP Securities - MarketBeat
Kura Oncology (NASDAQ:KURA) Price Target Raised to $40.00 - MarketBeat
Barclays PLC Buys 84,563 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Leerink Partnrs Predicts Kura Oncology Q2 Earnings - MarketBeat
Leerink Partnrs Predicts Kura Oncology Q1 Earnings - Defense World
A History of Outperforming Analyst Forecasts and Beating the Odds: Kura Oncology Inc (KURA) - SETE News
Kura Oncology stock target raised to $40 by H.C. Wainwright - MSN
BTIG cuts Kura Oncology stock rating to Neutral - MSN
Kura Oncology (NASDAQ:KURA) Trading 6.7% HigherStill a Buy? - MarketBeat
Leerink Partnrs Comments on Kura Oncology Q2 Earnings - Defense World
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Kura Oncology reports inducement grants under Nasdaq listing rule - TipRanks
Kura Oncology Expands Team with Strategic Stock Options PackageInside the $8.25/Share Deal - StockTitan
Kura/Kyowa Kirin’s Ziftomenib Scores In NPM1m AML, But Differentiation Is Key - News & Insights
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML - BioWorld Online
SG Americas Securities LLC Buys New Shares in Kura Oncology, Inc. (NASDAQ:KURA) - MarketBeat
Kura Oncology Cancer Study Hits Primary Goal, Lays Out Plans For Phase 3 Studies - Benzinga India
Kura Oncology falls despite trial success; rival Syndax gains - Seeking Alpha
Kura, Kyowa hail ph. 2 win for leukemia drug, but hold back data - Fierce Biotech
Market Watch Highlights: Kura Oncology Inc (KURA) Ends on an Upturn Note at 9.05 - The Dwinnex
Kura Oncology price target raised to $36 from $34 at Wedbush - TipRanks
BTIG cuts Kura Oncology stock rating to Neutral By Investing.com - Investing.com South Africa
Kura Eyes FDA Filing After Pivotal AML Win, but Investors Aren’t Impressed - BioSpace
A new trading data show Kura Oncology Inc (KURA) is showing positive returns. - SETE News
Kura stock slides 7% following ziftomenib update - MSN
Kura to take AML drug ziftomenib to regulators after mid-stage win - The Pharma Letter
Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs - The Manila Times
Senior Director, Investor Relations - Built In
Kura stock slides 7% following ziftomenib update (KURA:NASDAQ) - Seeking Alpha
Kura Oncology And Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial - Marketscreener.com
Kura Oncology Inc Stock (KURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kura Oncology Inc Stock (KURA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Leoni Mollie | Chief Medical Officer |
Jan 28 '25 |
Sale |
7.87 |
4,963 |
39,068 |
88,253 |
| Bair Teresa Brophy | Chief Legal Officer |
Jan 28 '25 |
Sale |
7.87 |
7,281 |
57,315 |
107,948 |
| FORD KATHLEEN | Chief Operating Officer |
Jan 28 '25 |
Sale |
7.87 |
1,817 |
14,303 |
21,367 |
| Burrows Francis | Chief Scientific Officer |
Jan 28 '25 |
Sale |
7.87 |
2,166 |
17,051 |
20,705 |
| Powl Brian T. | Chief Commercial Officer |
Jan 28 '25 |
Sale |
7.87 |
1,583 |
12,461 |
59,667 |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):